Diabetes is the most common cause of end-stage kidney disease, and its incidence and prevalence are projected to double by 2030.1 During the past 3 decades, major studies to understand albuminuric kidney disease progression secondary to diabetes have been performed.2,3 Today, it is well established that diabetic kidney disease associated with albuminuria with albumin excretion > 300 mg/d is slowed by the use of renin-angiotensin system (RAS) blockers.4-6 Since this observation in 2001, there have been many trials attempting to register drugs that further slow diabetic kidney disease progression secondary to type 2 diabetes.